Do GLP-1 Drugs Cause Muscle Loss? What Science Shows

Quick Answer

Yes, some lean mass can be lost during treatment with GLP-1–based weight-loss medications.

But the common claim that drugs such as semaglutide or tirzepatide simply “burn away muscle” is too simplistic.

Clinical studies generally show that most of the weight lost is fat mass, while a smaller proportion comes from lean mass. Recent analyses suggest that roughly one-quarter to one-third of total weight loss may come from lean tissue, although the amount varies substantially between studies and medications.

There is also an important distinction between lean mass and skeletal muscle. Common body-composition methods such as DXA include water, organs and other non-fat tissues within lean mass, so a decline in lean mass cannot automatically be interpreted as an equivalent loss of functional muscle.

The practical concern is therefore real but more nuanced than the headlines suggest. Preserving muscle through resistance training, adequate nutrition and appropriate clinical monitoring is particularly important during large or rapid weight loss.

What the Science Says

Large weight loss usually involves losing both fat and some lean tissue, whether that weight loss comes from diet, medication or other interventions. GLP-1 receptor agonists and related incretin drugs are no exception.

In the STEP 1 body-composition substudy, adults receiving semaglutide lost about 15% of their body weight over 68 weeks. Fat mass decreased by 19.3%, while lean body mass fell by 9.7%. Because fat was lost more rapidly, lean mass actually represented a greater proportion of body weight after treatment.

Similar results have been reported with tirzepatide. In the SURMOUNT-1 DXA substudy, body weight fell by 21.3%, fat mass by 33.9% and lean mass by 10.9% over 72 weeks. About 75% of the weight lost was fat and approximately 25% was lean mass.

A 2026 meta-analysis comparing incretin therapies with lifestyle interventions found that lean mass accounted for about 25% to 39% of weight lost with these medications. Importantly, the proportion was broadly similar to that seen with intensive lifestyle-induced weight loss, while programs that incorporated resistance training preserved lean mass more effectively.

So GLP-1–based treatments can clearly reduce absolute lean mass. What remains less certain is whether they cause an unusually large or clinically important loss of skeletal muscle beyond what might be expected from substantial weight reduction itself.

Lean Mass Is Not the Same as Muscle

This distinction matters more than it may seem.

DXA scans divide body mass broadly into fat mass, bone mineral content and lean soft tissue. Lean mass therefore includes skeletal muscle, but also water, organs and other fat-free tissues.

Rapid changes in hydration and glycogen can also influence some body-composition measurements.

So if a study reports that someone lost 4 kg of lean mass, it does not necessarily mean that they lost 4 kg of actual contractile muscle tissue.

This is one reason headlines claiming that GLP-1 drugs cause dramatic muscle wasting can overstate what the studies have actually measured.

Is the Amount of Lean-Mass Loss Abnormal?

This remains one of the major scientific questions.

Weight loss from caloric restriction normally includes some lean tissue. A 2026 meta-analysis found that lifestyle-induced weight loss produced a lean-mass proportion broadly comparable with incretin therapy overall.

However, another major 2026 systematic review found that muscle-related losses exceeded predefined expected benchmarks in roughly two-thirds of incretin interventions. The authors also emphasized substantial variation between studies and measurement methods and called for better trials assessing muscle function directly.

The fairest conclusion is therefore that meaningful lean-mass loss can occur and deserves attention, but it has not been established that everyone taking a GLP-1 drug experiences pathological muscle wasting.

What About Strength and Physical Function?

Losing lean mass does not necessarily mean becoming weaker.

In the prospective SEMALEAN study, people treated with semaglutide initially lost lean mass, but it stabilized later in treatment. At 12 months, handgrip strength had actually improved.

Tirzepatide trials have also reported improvements in patient-reported physical functioning, particularly among people who began treatment with poorer physical function.

These observations do not prove that muscle loss is irrelevant. They show why muscle mass, quality, strength and physical function should be considered separately.

Limitations Summary

Several limitations make this question harder than it first appears.

Many GLP-1 trials were designed primarily to measure weight loss rather than muscle health. Body-composition substudies often contain only a fraction of the participants in the main trial.

DXA and bioelectrical impedance measure lean or fat-free mass rather than skeletal muscle directly, while CT and MRI provide different information. This makes results difficult to compare across studies. A major 2026 systematic review found substantial heterogeneity and noted that objective physical-function outcomes were largely missing from the relevant randomized trials.

We also have limited long-term evidence in populations where muscle preservation may matter most, including older adults, people with low baseline muscle mass, frailty or sarcopenia, and individuals experiencing very rapid or very large weight loss.

Finally, semaglutide, liraglutide and tirzepatide should not automatically be assumed to have identical body-composition effects.

What This Means in Real Life

The goal during GLP-1–assisted weight loss should not simply be to make the number on the scale as low as possible.

It should be to lose primarily fat while preserving as much muscle, strength and nutritional adequacy as reasonably possible.

For people using these medications, resistance exercise becomes particularly relevant. A 2025 joint advisory from the American Society for Nutrition, The Obesity Society, Obesity Medicine Association and American College of Lifestyle Medicine emphasizes resistance training and adequate nutrition as key strategies for preserving muscle during GLP-1 therapy.

Adequate protein intake is also important, although simply eating more protein is not a substitute for loading the muscles through resistance exercise. Individual protein requirements can differ considerably with age, body size, kidney function, dietary intake and activity level, so a single high-protein target is not appropriate for everyone.

People who are older, already have low muscle mass, become unusually weak, eat very little because of medication-related appetite suppression, or lose weight particularly rapidly may warrant closer clinical attention to nutrition, strength and body composition.

Key Takeaway

GLP-1 weight-loss drugs can reduce lean mass—but that is not the same as proving they cause pathological muscle wasting.

Most of the weight lost with semaglutide and tirzepatide appears to come from fat. Some lean tissue is lost as well, much as it can be during substantial weight loss from other methods.

The most useful response is not to avoid effective obesity treatment solely because of muscle-loss headlines, but to make muscle preservation part of the weight-loss strategy through resistance exercise, adequate nutrition and appropriate monitoring.

Sources

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review

John A Batsis, Alessandro Gavras, Danae C Gross, C Ray Cheever, Bruna R Da Silva, Luiz Fernando Meira Filho, Emily P Jones, Dakota Batchek, Simone Khandpekar, Rohan Patel, Bilal Awkal, Annamarie Pape, Marianne Bahna, Mauro Zamboni, Carla M Prado. Annals of Internal Medicin. 2026.

Systematic Review DOI: 10.7326/ANNALS-25-00478 PMID: 41996180

Major contemporary synthesis examining fat mass, fat-free mass, lean tissue and muscle-related indices across incretin trials. Across the included studies, reductions in muscle-related indices varied substantially. The review also highlights the limitations of current body-composition methods and the shortage of objective physical-function outcomes

Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Naseem Eisa, Omar Barood. Diabetes, Obesity and Metabolism. 2026.

Meta Analysis DOI: 10.1111/dom.70666 PMID: 41877354

Key evidence comparing incretin-associated lean-mass loss with lifestyle-induced weight loss. Twenty RCTs involving 15,782 participants were included. Lean mass accounted for approximately 25–39% of total weight loss with incretin therapy and was broadly comparable with lifestyle intervention; resistance-training programs showed better lean-mass preservation.

Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight

Michelle Look, Julia P Dunn, Robert F Kushner, Dachuang Cao, Charles Harris, Theresa Hunter Gibble, Adam Stefanski, Ryan Griffin. Diabetes, Obesity and Metabolism. 2025.

Randomized Controlled Trial PMID: 39996356

Primary tirzepatide body-composition evidence. At 72 weeks, tirzepatide reduced weight by 21.3%, fat mass by 33.9% and lean mass by 10.9%. Approximately three-quarters of the lost weight was fat mass. Conflict-of-interest note: Several authors were Eli Lilly employees/shareholders or reported relationships with the manufacturer. This should be considered when weighing the evidence, particularly until findings are replicated independently.

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study

John P H Wilding, Rachel L Batterham, Salvatore Calanna, Luc F Van Gaal, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F Kushner. Journal of the Endocrine Society. 2021.

Randomized Controlled Trial DOI: 10.1210/jendso/bvab048.030 PMID: PMC8089287

Foundational semaglutide body-composition evidence. Semaglutide reduced body weight by approximately 15%, fat mass by 19.3% and lean body mass by 9.7%, while the relative proportion of lean mass increased.

Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

Mathieu Alissou, Thomas Demangeat, Vanessa Folope, Hélène Van Elslande, Hélène Lelandais, Julia Blanchemaison, Pierre-Emmanuel Cailleaux, Suzan Guney, Alexandra Aupetit, Agnès Aubourg, Clément Rapp, André Petit, Morgane Godin, Luc Vignal, Sébastien Grigioni, Pierre Déchelotte, Guillaume Colange, Moïse Coëffier, Najate Achamrah. Diabetes, Obesity and Metabolism. 2025.

Clinical Trial PMID: 41068996

Provides information not only about body composition but also muscle function. Lean mass initially declined and later stabilized, while handgrip strength improved over 12 months.

Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M Kane, Jasdeep Saluja, Deepa Sannidhi, Fatima Cody Stanford, Emily A Callahan. American Journal of Clinical Nutrition. 2025.

Expert Review DOI: 10.1016/j.ajcnut.2025.04.023 PMID: 40450457

Practical guidance on nutrition, resistance exercise, muscle preservation and monitoring during GLP-1 therapy.

Medical disclaimer: This article is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional for personal medical decisions.

Do GLP-1 Weight Loss Drugs Cause Muscle Loss?